Inc. ranks Dante Genomics #19 of the 1,125 fastest-growing companies in the U.S. and regionally #2 of the 169 fastest-growing companies in the Northeast.
The Annual Inc. Magazine Regionals 2023 ranking of the fastest-growing companies from every corner of the country names Dante Genomics in top spot for its 3,873% growth rate over two years.
“Growth comes from every function, from every employee, and most importantly, means more patients we can reach and help,” said Andrea Riposati, co-founder and CEO of Dante Genomics.
Dante is revolutionizing the global genetic testing industry, offering clinical whole genome sequencing at an affordable price with a vision to sequence your data once and query for a lifetime when you need it.
Dante recently announced the commercial launch of its proprietary B2B Avanti Software with a plug-and-play approach to enable genomic interpretation at scale within minutes. This software solution takes the raw data output of a sequencer and turns it into an input to deliver clinically actionable genomic reports in minutes. Dante’s software offers a catalog of more than 125 wellness and clinical reports offering insights into your health and wellness with results you can act on. For more information about the Avanti software or to try it for yourself, please visit avanti.dantegenomics.com.
The Inc. Regionals 2023 is an extension of the Inc. 5000, which lists the 5,000 fastest-growing private companies in the US. The Inc. Regionals are rankings of the fastest growing companies in a particular region, including Mid-Atlantic, Midwest, Northeast, Pacific, Rocky Mountains, Southeast and Southwest. Companies are ranked according to the percentage growth of their annual revenue over a two-year period.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and software. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.